ResMed Inc. (RMD) shares surged 5.61% during the after-hours session on Thursday following the release of the company's better-than-expected fiscal second-quarter results.

The medical device maker reported adjusted earnings per share of $2.81, exceeding analyst estimates of $2.72, while revenue grew 11% year-over-year to $1.42 billion, also beating expectations. The strong performance was driven by robust demand for ResMed's sleep apnea and respiratory care devices, with the company noting that gross margin expanded to 62.3% due to manufacturing efficiencies and component cost improvements.

Additionally, ResMed announced a quarterly cash dividend of $0.60 per share and reported repurchasing 704,000 shares for $175 million during the quarter. CEO Mick Farrell expressed confidence in the company's growth trajectory, stating that ResMed will continue to invest in innovation to scale digital health capabilities while delivering sustainable, profitable growth in the second half of fiscal 2026.